Jacob sits down with Insitro CEO Daphne Koller to discuss founding Coursera, where and how ML can drive the most impact in drug development, and if foundation models can transform core drug discovery work and edtech.

(00:00) - intro

(00:54) - Daphne’s journey

(09:18) - AI and biology discovery

(10:59) - insitro vs. traditional pharma

(20:04) - phenotyping patients

(26:01) - early mistakes

(29:51) - the future of data

(35:33) - partnering with larger pharma companies

(38:17) - impact of LLMs on biopharma

(44:04) - over-hyped/under-hyped

With your co-hosts:

@jasoncwarner - Former CTO GitHub, VP Eng Heroku & Canonical

@ericabrescia - Former COO Github, Founder Bitnami (acq’d by VMWare)

@patrickachase - Partner at Redpoint, Former ML Engineer LinkedIn

@jacobeffron - Partner at Redpoint, Former PM Flatiron Health

Ep 10: Insitro CEO Daphne Koller on Using ML to Change Drug Discovery 49:01 Share

Unsupervised Learning

Shownotes Transcript

Ep 10: Insitro CEO Daphne Koller on Using ML to Change Drug Discovery